Dr. Sarina Piha-Paul, MD

• Medical Oncology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Lsu Health Sciences Center New Orleans School Of Medicine

  Medical School, 2002

• Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib, 2019-09-23

• A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor ofHER2, in patients with advanced solid tumors withHER2orHER3aberrations, 2021-03-27

• PIK3CA, and PTEN Aberrations in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors: Experience with 1,656 Patients at MD Anderson Cancer Center, 2014-01-16

• BRAFmutation testing with a rapid, fully integrated molecular diagnostics system, 2015-07-27

• A mutation-specific, single-arm, phase 2 study of dovitinib in patients with advanced malignancies, 2020-04-07

• Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic, 2018-09-04

• Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors, 2017-11-21

• Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection ofKRASMutations in Urine Cell-Free DNA from Patients with Advanced Cancers, 2017-01-17

• Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway, 2014-03-14

• Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer andPIK3CAmutations, 2013-10-03

• Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment, 2021-07-29

• Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study, 2019-11-05

• Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus, 2014-03-20

• Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors, 2021-12-29

• Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial, 2021-02-11

• Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors, 2014-11-04

• Outcomes of patients with advanced cancer andKRASmutations in phase I clinical trials, 2014-08-10

• Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies, 2021-03-05

• Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial, 2020-04-20

• Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer, 2018-11-15

• Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors withPIK3CAorAKTmutations, and/or PTEN loss/PTENmutation, 2019-07-05

• A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation, 2023-06-14

• Factors Affecting Symptom Presentation in an Early-Phase Clinical Trials Clinic Patient Population, 2019-11-25

• METabnormalities in patients with genitourinary malignancies and outcomes withc-METinhibitors, 2014-07-03

• 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one National Harbor, MD, USA. 9-13 November 2016, 2016-11-16

• Associations between the gut microbiome and fatigue in cancer patients, 2021-03-12

• PIK3CAmutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early phase clinical trials, 2012-10-12

• Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study, 2021-09-25

• FBXW7Mutations in Patients with Advanced Cancers: Clinical and Molecular Characteristics and Outcomes with mTOR Inhibitors, 2014-02-19

• Report of the First International Symposium on NUT Carcinoma, 2022-06-13

• Signature program: a platform of basket trials, 2018-04-20

• METaberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit, 2014-03-16

• Phase I Study of Anti-VEGF Monoclonal Antibody Bevacizumab and Histone Deacetylase Inhibitor Valproic Acid in Patients with Advanced Cancers, 2014-01-17

• A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer, 2014-10-18

• Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors, 2017-02-13

• Phase I Study of the Combination of Vemurafenib, Carboplatin, and Paclitaxel in Patients withBRAF-Mutated Melanoma and Other Advanced Malignancies, 2018-11-01

• Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study, 2021-10-27

• Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences, 2022-05-24

• Incidence of immune-related adverse events and its association with treatment outcomes: The MD Anderson Cancer Center experience, 2017-11-21

• Phase I study of everolimus, letrozole, and trastuzumab in patients with hormone receptor-positive metastatic breast cancer or other solid tumors, 2020-10-28

• Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma, 2017-12-28

• PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes, 2012-11-30

• Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy, 2016-08-31

• Pediatric Patients with Refractory Central Nervous System Tumors: Experiences of a Clinical Trial Combining Bevacizumab and Temsirolimus, 2017-11-07

• Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers, 2017-10-19

• Analysis ofMETGenetic Aberrations in Patients With Breast Cancer at MD Anderson Phase I Unit, 2014-06-23

• Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer, 2019-03-04

• Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study, 2021-04-28

• Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience, 2017-08-03

• Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial, 2022-08-23

• TargetingERBB2(HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications, 2019-10-21

• Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies, 2015-02-25

• Clinical next generation sequencing to identify actionable aberrations in a phase I program, 2015-05-08

• Combining Erlotinib and Cetuximab is Associated with Activity in Patients with Non Small Cell Lung Cancer (including Squamous Cell Carcinomas) and Wild-TypeEGFRor Resistant Mutations, 2013-08-20

• Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies, 2019-09-16